Clinical Trial Update: Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine [Phase 2]

View source ↗

Summary

The Phase II study evaluating RP101 in combination with gemcitabine for pancreatic cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• RP101 (RP101)

Snippet

Sponsor: SciClone Pharmaceuticals | Conditions: Pancreatic Cancer | Phase 2 | Status: TERMINATED